ORNA Lipid 10a-26|Ionizable Lipid for LNP

Cas No.:	2648693-32-5
Chemical Name:	ORNA Lipid 10a-26
Synonyms:	Decanoic acid, 2-hexyl-, 1,1′-[[[3-(1H -imidazol-1-yl)propyl]imino]di-6, 1-hexanediyl] ester (ACI),Lipid A26,ORNA Lipid 10a26
SMILES:	O=C(OCCCCCCN(CCCN1C=NC=C1)CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)C(CCCCCC)CCCCCCCC
Formula:	C₅₀H₉₅N₃O₄
M.Wt:	802.31
Purity:	>95%
Publication:	Circular RNA compositions for targeted and efficient therapeutic protein expression in immune cells for treating cancer or autoimmune disease By: Wesselhoeft, Alex; Goodman, Brian-WO2021189059 A2 2021-09-23

Testing Data PDF

Cat. No.	Product name	Field of application
DC67553	Lipid PL40	PL-40 is a cardiolipin-mimetic ionizable lipid engineered for high-efficiency, antibody-free mRNA delivery to T cells. PL 40 LNPs exhibit a mean particle size of 120 nm, zeta potential of -5.19 mV, and >80% mRNA encapsulation efficiency, with excellent plasma stability (≤5% size change after 6h in serum). Cryo-TEM reveals polyhedral nanoparticles with phase-separated domains, while SAXS confirms tight mRNA packing (d-spacing: ~3 nm vs. 6.64 nm in conventional LNPs). AFM demonstrates exceptional rigidity (high bending modulus), enabling T cell-selective uptake via actin-mediated endocytosis (>2× higher than ALC0315 LNPs).In primary human T cells, PL40 LNPs achieve >90% transfection at 0.5 μg mRNA dose and sustain >100× higher luciferase expression than benchmark lipids. When delivering circular RNA, they extend protein expression >5 days with superior spleen tropism (spleen:liver ratio = 2.63). Crucially, they reprogram T cells into functional CAR-Ts in vivo without antibody conjugation, evading exhaustion markers (no Tim-3/PD-1 upregulation). Therapeutically, PL40-based uPAR-targeted CAR mRNA reduces liver fibrosis (collagen↓50%, ALT↓50%) and rheumatoid arthritis severity (clinical scores↓60%) by clearing senescent cells. Humanized anti-uPAR CARs delivered via PL40 show near-complete cytotoxicity (>95%) against uPAR+ cells, underscoring clinical translatability.
DC82209	ORNA Lipid 10a-26	Lipid 10a-26 is an ionizable lipid developed by Orna Therapeutics for lipid nanoparticle (LNP) formulations. It features a biodegradable ester backbone and an ionizable headgroup, enabling efficient encapsulation and delivery of circular RNA (oRNA). Experimental data show that Lipid 10a-26 mediates robust protein expression in hepatocytes and immune cells (e.g., T cells), with strong liver-targeting specificity observed in vivo. Its optimized hydrolysis profile ensures stable oRNA delivery and reduced immunogenicity. For instance, LNPs formulated with Lipid 10a-26 (molar ratio 50:10:38.5:1.5) demonstrate high transfection efficiency in splenic B cells and sustained therapeutic protein production.The lipid’s design balances efficacy and safety, making it ideal for applications like CAR-T therapy and hepatic protein replacement.